Celltrion’s Biosimilar Rituximab Brings Indication Carve Outs To US FDA Panel Review

 
• By Sue Sutter
  
PS1809_Wood Carving_334212629_1200.jpg
Celltrion used its carving tools to craft a label for biosimilar rituximab.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers